Clinical demographics of the discovery cohort and replication cohort
| Covariate . | Discovery mean/% (all) (n = 103) . | Discovery mean/% (>49 mg/week) (n = 58) . | Discovery mean (<35 mg/week) (n = 45) . | Replication cohort mean/% . |
|---|---|---|---|---|
| Dose | 49.16 mg/wk | 66.38 mg/wk | 26.97 mg/wk | 43.80 mg/wk |
| Gender | 68.00% female | 67.2% female | 68.89% female | 61.39% female |
| Age | 56.75 y | 50.38 y | 64.96 y | 57.58 y |
| Height | 168.20 cm | 168.83 cm | 167.40 cm | 169.60 cm |
| Weight | 92.37 kg | 96.43 kg | 87.13 kg | 92.05 kg |
| Aspirin | 26.21% | 12.07% | 44.44% | — |
| Amiodarone | 0.97% | 0% | 2.22% | 4.30% |
| Phenytoin | 0.97% | 0% | 2.22% | — |
| Carbamazepine | 1.94% | 3.45% | 0% | — |
| Rifampin | 2.91% | 3.45% | 2.22% | — |
| Indication (VTE) | 64.71% | 82.75% | 40.91% | 47.04% |
| Covariate . | Discovery mean/% (all) (n = 103) . | Discovery mean/% (>49 mg/week) (n = 58) . | Discovery mean (<35 mg/week) (n = 45) . | Replication cohort mean/% . |
|---|---|---|---|---|
| Dose | 49.16 mg/wk | 66.38 mg/wk | 26.97 mg/wk | 43.80 mg/wk |
| Gender | 68.00% female | 67.2% female | 68.89% female | 61.39% female |
| Age | 56.75 y | 50.38 y | 64.96 y | 57.58 y |
| Height | 168.20 cm | 168.83 cm | 167.40 cm | 169.60 cm |
| Weight | 92.37 kg | 96.43 kg | 87.13 kg | 92.05 kg |
| Aspirin | 26.21% | 12.07% | 44.44% | — |
| Amiodarone | 0.97% | 0% | 2.22% | 4.30% |
| Phenytoin | 0.97% | 0% | 2.22% | — |
| Carbamazepine | 1.94% | 3.45% | 0% | — |
| Rifampin | 2.91% | 3.45% | 2.22% | — |
| Indication (VTE) | 64.71% | 82.75% | 40.91% | 47.04% |